ArticleCase reports in hematology2026
Management Challenges and Outcomes of Bronchiolitis Obliterans Syndrome After Hematopoietic Stem Cell Transplantation: First Case Series Report From Vietnam.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management Challenges and Outcomes of Bronchiolitis Obliterans Syndrome After Hematopoietic Stem Cell Transplantation: First Case Series Report From Vietnam.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiolitis obliterans syndrome (BOS) is a serious pulmonary manifestation of chronic graft-versus-host disease (cGvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Data from low- and middle-income countries remain scarce. We conducted a case series of 11 patients diagnosed with BOS between November 2023 and June 2025 at the National Lung Hospital, Hanoi, Vietnam. Clinical characteristics, treatments, pulmonary function, and outcomes over 12 months were analyzed. The series was predominantly male (81.8%), with a median age of 34 years (range, 12-57). The median time from HSCT to BOS diagnosis was 24 months (range, 11-72). All patients received fluticasone, azithromycin, montelukast (FAM) plus long-acting bronchodilators, and 4 patients also received systemic corticosteroids. Median baseline forced expiratory volume in one second (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.